Levodopa Alone and in Combination with a Peripheral Decarboxylase Inhibitor Benserazide (Madopar) in the Treatment of Parkinson's Disease: A Controlled Clinical Trial

Overview

Journal J Neurol

Specialty Neurology

Date 1975 Dec 2

PMID 56427

Citations 4

Authors

U K Rinne

E BIRKET-SMITH

E Dupont

E Hansen

M Hyyppa

R Marttila

B Mikkelsen

H Pakkenberg

J Presthus

Affiliations

Soon will be listed here.

Abstract

A combination of levodopa and the extracerebrally acting decarboxylase inhibitor benserazide (ratio 4:1) (Madopar), was compared with levodopa alone in a controlled double-blind clinical multicenter trial on 94 patients with Parkinson's disease. During 4 months of therapy levodopa + benserazide proved superior to levodopa on several accounts. Nausea and vomiting occurred with statistically significant less severity and frequency. Clinical improvement expressed through improvement in Webster rating occurred sooner and was all together greater. The treatment schedules did not differ with regard to other side effects, in particular involuntary movements and reduction in supine blood pressure. Neither treatment seemed to influence liver function, renal function and hematological parameters.

Citing Articles

Tyrosine Hydroxylase Inhibitors and Dopamine Receptor Agonists Combination Therapy for Parkinson's Disease.

Yi L, Tan E, Zhou Z Int J Mol Sci. 2024; 25(9).

PMID: 38731862 PMC: 11083272. DOI: 10.3390/ijms25094643.

Evidence for dopaminergic involvement in endogenous modulation of pain relief.

Desch S, Schweinhardt P, Seymour B, Flor H, Becker S Elife. 2023; 12.

PMID: 36722857 PMC: 9988263. DOI: 10.7554/eLife.81436.

Cystathionine-β-Synthase: Molecular Regulation and Pharmacological Inhibition.

Zuhra K, Augsburger F, Majtan T, Szabo C Biomolecules. 2020; 10(5).

PMID: 32365821 PMC: 7277093. DOI: 10.3390/biom10050697.

Current status of symptomatic medical therapy in Parkinson's disease.

Factor S Neurotherapeutics. 2008; 5(2):164-80.

PMID: 18394561 PMC: 5084161. DOI: 10.1016/j.nurt.2007.12.001.

References

Rinne U, SONNINEN V, Sirtola T . Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor. Z Neurol. 1972; 202(1):1-20. DOI: 10.1007/BF00316422. View

Constantinidis J, de la Torre J, Tissot R, GEISSBUHLER F . [The capillary barrier for dopa in brain and different organs]. Psychopharmacologia. 1969; 15(2):75-87. DOI: 10.1007/BF00407039. View

Yahr M, Duvoisin R, Schear M, BARRETT R, HOEHN M . Treatment of parkinsonism with levodopa. Arch Neurol. 1969; 21(4):343-54. DOI: 10.1001/archneur.1969.00480160015001. View

Constantinidis J, Siegfried J, Frigyesi T, Tissot R . Parkinson's disease and striatal dopamine: in vivo morphological evidence for the presence of dopamine in the human brain. J Neural Transm. 1974; 35(1):13-22. DOI: 10.1007/BF01245332. View

Calne D, STERN G, Spiers A, Laurence D . L-dopa in idiopathic parkinsonism. Lancet. 1969; 2(7628):973-6. DOI: 10.1016/s0140-6736(69)90536-4. View

Pakkenberg H, Dupont E, Garde B, Hansen E, MELSEN S, Vestberg F . [Levodopa and Parkinsonism. A double-blind study]. Ugeskr Laeger. 1971; 133(46):2275-9. View

BIRKET-SMITH E . Abnormal involuntary movements induced by anticholinergic therapy. Acta Neurol Scand. 1974; 50(6):801-11. DOI: 10.1111/j.1600-0404.1974.tb02820.x. View

Rinne U, SONNINEN V, Siirtola T . Plasma concentration of levodopa in patients with Parkinson's disease. Eur Neurol. 1973; 10(5):301-10. DOI: 10.1159/000114285. View

Pletscher A, BARTHOLINI G . Selective rise in brain dopamine by inhibition of extracerebral levodopa decarboxylation. Clin Pharmacol Ther. 1971; 12(2):344-52. DOI: 10.1002/cpt1971122part2344. View

10.

WORM-PETERSEN J, Dupont E, Mikkelsen B . [L-Dopa therapy in Parkinson's disease. A double-blind study]. Ugeskr Laeger. 1971; 133(47):2321-6. View

11.

Gerlach J, REISBY N, RANDRUP A . Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacologia. 1974; 34(1):21-35. DOI: 10.1007/BF00421217. View

12.

Presthus J, Holmsen R . Appraisal of long-term levodopa treatment of parkinsonism with special reference to therapy limiting factors. Acta Neurol Scand. 1974; 50(6):774-90. DOI: 10.1111/j.1600-0404.1974.tb02818.x. View

13.

MARS H . Modification of levodopa effect by systemic decarboxylase inhibition. Arch Neurol. 1973; 28(2):91-5. DOI: 10.1001/archneur.1973.00490200039004. View

14.

Schneider E, FISCHER P, Jacobi P, MAXION H . [Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease]. Arch Psychiatr Nervenkr (1970). 1973; 217(1):95-112. DOI: 10.1007/BF02552835. View

15.

Rinne U, SONNINEN V . Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor. Arch Neurol. 1973; 28(2):107-10. DOI: 10.1001/archneur.1973.00490200055007. View

16.

BARTHOLINI G, Pletscher A . Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase. J Pharmacol Exp Ther. 1968; 161(1):14-20. View

17.

Rinne U, SONNINEN V . A double blind study of 1-dopa treatment in Parkinson's disease. Eur Neurol. 1968; 1(3):180-91. DOI: 10.1159/000113660. View

18.

BIRKET-SMITH E . Abnormal involuntary movements in relation to anticholinergics and levodopa therapy. Acta Neurol Scand. 1975; 52(2):158-60. DOI: 10.1111/j.1600-0404.1975.tb05769.x. View

19.

BARTHOLINI G, BURKARD W, Pletscher A . Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature. 1967; 215(5103):852-3. DOI: 10.1038/215852b0. View

20.

WEBSTER D . Critical analysis of the disability in Parkinson's disease. Mod Treat. 1968; 5(2):257-82. View